Answer:
TRUE
Explanation:
If the population follows a logistic growth curve, the graph of P vs t will look like the diagram below.
The rate of growth (P') increases slowly at first, then increases rapidly from 2 to 4, and then slows down, but always P > 0.
The graph has an inflection point at (3, 1000). That's the point at which the rate of growth starts slowing down.
When t < 3, P'' > 0.
When t = 3, P'' = 0.
When t > 3, P'' < 0, because the rate of population growth is slowing down.
Thus, if the population is in the final phase of logistic growth, the population is increasing at a decreasing rate (TRUE)..
Answer:
Answer is A. Cdk7 of the CAK (TFIIH component) phosphorylates Cyclin 8 of the Mediator to down regulate promoter activity.
Refer below.
Explanation:
Cdk7 of the CAK (TFIIH component) phosphorylates Cyclin 8 of the Mediator to down regulate promoter activity is a FALSE STATEMENT.
During anaphase, sister chromatids are pulled to opposite poles by the spindle fibers in preparation for cleavage.
Answer:
Thermosensitive liposomes (TSL) are promising tools used to deliver drugs to targeted region when local hyperthermia is applied (∼40–42°C) which triggers the membrane phase transformation from a solid gel-like state to a highly permeable liquid state. Selective lipid components have been used to in TSL formulations to increase plasma stability before hyperthermia and speed drug release rate after. Two generations of TSL technology have been developed. The traditional thermal sensitive liposomes (TTSL) have utilized DPPC and DSPC as a combination. The second generation, lysolipid thermally sensitive liposomes (LTSL) technology, has been developed with incorporation of lysolipids that form stabilized defects at phase transition temperature. LTSL maintains certain favorable attributes:
High percentage of lysolipids incorporation;
Minimum leakage for therapeutical drugs encapsulation;
Ultrafast drug release upon heating (3.5 times enhanced compared to TTSL). For example, ThermoDox, a commonly used LTSL drug for cancer, has been reported to release 100% of the encapsulated doxorubicin within 30s;
First and most successful formulation for intravascular drug release.
Explanation:
https://www.creative-biostructure.com/Lysolipid-Thermally-Sensitive-Liposomes-Production-612.htm
